<DOC>
	<DOCNO>NCT02151474</DOCNO>
	<brief_summary>The purpose study explore safety , tolerability efficacy INCB047986 , subject moderate severe rheumatoid arthritis .</brief_summary>
	<brief_title>INCB047986 Rheumatoid Arthritis</brief_title>
	<detailed_description>This double-blind , placebo-controlled study 4 parallel treatment group . Subjects screen 28 day study drug administration ensure eligibility criterion meet . On Day 1 , subject randomize 1 4 dose group 15 subject ( INCB047986 4 mg , 8 mg , 12 mg , placebo QD ) . Study drug self administer Days 1 28 . A follow-up telephone call subject ass safety occur Day 42 . A final safety efficacy evaluation perform Day 58 visit .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Men woman age 18 75 year , inclusive . Body mass index 18 40 kg/m^2 , inclusive . Subjects must diagnosis rheumatoid arthritis ( RA ) least 6 month ' duration time screen must satisfy ACR/European League Against Rheumatism ( EULAR ) 2010 Classification Criteria ( Appendix B ) . Subjects must active moderate severe RA determine follow : ≥ 6 tender joint ( 28 joint count ) , ≥ 4 swollen joint ( 28 joint count ) , CRP level ≥ 6 mg/L . Subjects must negative tuberculosis ( TB ) test ( QuantiFERON®TB Gold test purify protein derivative ( PPD ) ) screen . Current recent history severe and/or progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurological , cerebral disease . Current recent history ( &lt; 30 day screen and/or &lt; 45 day randomization ) clinically meaningful bacterial , fungal , parasitic , mycobacterial infection . Onset RA age 16 year . History know currently suspect inflammatory disease RA Current regimen prednisone equivalent average daily dose &gt; 10 mg treat stable daily dose ≤ 10 mg &lt; 6 week . Previous treatment Janus kinase ( JAK ) inhibitor . Significant impairment bone marrow function present screen Receipt live vaccine within 2 month screen anticipated need live vaccine within 2 month last dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>